Article info
A difficult case
Cryptococcal meningoencephalitis in multiple sclerosis treated with fingolimod
- Correspondence to Dr Moneeb Nasir, The Royal London Hospital, London, UK; moneeb.nasir{at}nhs.net
Citation
Cryptococcal meningoencephalitis in multiple sclerosis treated with fingolimod
Publication history
- Accepted June 27, 2023
- First published October 6, 2023.
Online issue publication
November 23, 2023
Article Versions
- Previous version (23 November 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Update on disease-modifying therapies for multiple sclerosis
- ▼Fingolimod for multiple sclerosis
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis
- Tumefactive demyelination: an approach to diagnosis and management
- Disease modifying therapies for relapsing multiple sclerosis
- Fingolimod in multiple sclerosis: profile of use in habitual practice
- Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?
- SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod